about
Efficacy and safety of the oral Janus kinase inhibitor peficitinib (ASP015K) monotherapy in patients with moderate to severe rheumatoid arthritis in Japan: a 12-week, randomised, double-blind, placebo-controlled phase IIb studySome perspectives on network modeling in therapeutic target predictionDynamical and structural analysis of a T cell survival network identifies novel candidate therapeutic targets for large granular lymphocyte leukemia.MassSQUIRM: An assay for quantitative measurement of lysine demethylase activityThe JAK inhibitor tofacitinib suppresses synovial JAK1-STAT signalling in rheumatoid arthritis.Cyclin-dependent kinase inhibitor p21, via its C-terminal domain, is essential for resolution of murine inflammatory arthritisUpdates on Psoriasis and Cutaneous Oncology: Proceedings from the 2015 MauiDerm MeetingJAK inhibition using tofacitinib for inflammatory bowel disease treatment: a hub for multiple inflammatory cytokinesThe immunomodulatory effects of TNF-α inhibitors on human Th17 cells via RORγt histone acetylationTyrosine kinases in rheumatoid arthritis.JAK-STAT Signaling as a Target for Inflammatory and Autoimmune Diseases: Current and Future Prospects.JAK inhibition in inflammatory bowel disease.The expanding therapeutic armamentarium for inflammatory bowel disease: how to choose the right drug(s) for our patients?Updates on Psoriasis and Cutaneous Oncology: Proceedings from the 2017 MauiDerm Meeting.A review of tofacitinib efficacy in rheumatoid arthritis patients who have had an inadequate response or intolerance to methotrexate.Participation of PI3K, MAPK ERK1/2, and p38 in the realization of growth potential of mesenchymal precursor cells under in vitro conditions.Role of cAMP and IKK-2-dependent signaling in the realization of growth potential of mesenchymal progenitor cells.
P2860
Q24658506-9906BE77-A88F-4C3C-B4C6-475D943BD58CQ26825791-1C587DBE-9B20-4879-825D-DA6868B408EFQ34079139-227D6A86-F091-46F0-85AB-9AB6BD671473Q35592159-6DC05076-E21F-4778-A873-8B1F49FF5FF5Q35605477-984F7C98-CA81-4CE7-8207-5D93957BED62Q35658843-75B8EFA0-A193-44B9-B41E-A8DD79F4BC1FQ35822379-7D27EB72-C772-48A2-AD61-F8E634CAAF9EQ37148745-1287375E-ED16-4C33-ACBC-824C83B89270Q37702568-DE423772-91CC-44EB-8510-846D1443AA20Q38366902-DC037A48-CD5D-447D-A589-F683325EB984Q38751230-CA60B47A-0F6B-4962-B341-7601E647CBBCQ38761142-45C6BCDB-8968-466F-8F0E-5C26BA05097EQ44581309-24DB4134-83F7-4CD5-B88F-1CF8E06E21BAQ49210038-DBA5A586-75F6-4524-87B1-D23CA8368A43Q53791793-ECC818A9-B84A-482F-88EB-B2972EE2A70BQ54356823-C6235109-2F93-40CD-8052-4C39C89B10F4Q54391644-D85F0173-F09D-428B-9F6A-FACF20D88FFF
P2860
description
2009 nî lūn-bûn
@nan
2009 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Intracellular signal pathways: potential for therapies.
@ast
Intracellular signal pathways: potential for therapies.
@en
Intracellular signal pathways: potential for therapies.
@nl
type
label
Intracellular signal pathways: potential for therapies.
@ast
Intracellular signal pathways: potential for therapies.
@en
Intracellular signal pathways: potential for therapies.
@nl
prefLabel
Intracellular signal pathways: potential for therapies.
@ast
Intracellular signal pathways: potential for therapies.
@en
Intracellular signal pathways: potential for therapies.
@nl
P2860
P1476
Intracellular signal pathways: potential for therapies
@en
P2093
Harris Perlman
Melissa Mavers
P2860
P2888
P304
P356
10.1007/S11926-009-0054-9
P577
2009-10-01T00:00:00Z
P5875
P6179
1044391773